Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients

J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e348-e350. doi: 10.1111/jdv.15636. Epub 2019 May 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Enzyme Activation
  • Erdheim-Chester Disease / drug therapy*
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Female
  • Humans
  • MAP Kinase Kinase Kinases / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Sarcoidosis / chemically induced*

Substances

  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf
  • Extracellular Signal-Regulated MAP Kinases
  • MAP Kinase Kinase Kinases